Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
Christopher J O'Donnell, Bruce N Rogers, Brian S Bronk, Dianne K Bryce, Jotham W Coe, Karen K Cook, Allen J Duplantier, Edelweiss Evrard, Mihaly Hajós, William E Hoffmann, Raymond S Hurst, Noha Maklad, Robert J Mather, Stafford McLean, Frank M Nedza, Brian T O'Neill, Langu Peng, Weimin Qian, Melinda M Rottas, Steven B Sands, Anne W Schmidt, Alka V Shrikhande, Douglas K Spracklin, Diane F Wong, Andy Zhang, Lei Zhan. Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo efficacy in cognition models. Journal of medicinal chemistry. vol 53. issue 3. 2010-03-12. PMID:20043678. |
a novel alpha 7 nachr agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, cp-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and alzheimer's disease. |
2010-03-12 |
2023-08-12 |
Not clear |
Edgar Luttmann, Jürgen Ludwig, Anja Höffle-Maas, Marek Samochocki, Alfred Maelicke, Gregor Fel. Structural model for the binding sites of allosterically potentiating ligands on nicotinic acetylcholine receptors. ChemMedChem. vol 4. issue 11. 2010-01-28. PMID:19739198. |
current treatments of alzheimer's disease include the allosteric potentiation of nicotinic acetylcholine receptor (nachr) response. |
2010-01-28 |
2023-08-12 |
human |
Susanne Nikolaus, Christina Antke, Hans-Wilhelm Mülle. In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia. Behavioural brain research. vol 204. issue 1. 2009-12-01. PMID:19523490. |
alzheimer's disease is characterized by both pre-and postsynaptic deficiencies of the cholinergic system with decreases of cortical acetylcholine storage (one out of two reports) and both musarinic (seven out of 10 reports) and nicotinic cholinergic receptor binding (three out of six reports). |
2009-12-01 |
2023-08-12 |
Not clear |
Igor E Kasheverov, Yuri N Utkin, Victor I Tsetli. Naturally occurring and synthetic peptides acting on nicotinic acetylcholine receptors. Current pharmaceutical design. vol 15. issue 21. 2009-11-27. PMID:19601841. |
beta-amyloid, a peptide forming senile plaques in alzheimer's disease, also can bind to nachr, although the mode of binding is still unclear. |
2009-11-27 |
2023-08-12 |
Not clear |
Shigeki Moriguchi, Norifumi Shioda, Feng Han, Jay Z Yeh, Toshio Narahashi, Kohji Fukunag. Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation. Hippocampus. vol 19. issue 9. 2009-10-30. PMID:19253410. |
galantamine, a novel alzheimer's drug, is known to inhibit acetylcholinesterase activity and potentiate nicotinic acetylcholine receptor (nachr) in the brain. |
2009-10-30 |
2023-08-12 |
rat |
J R Ellis, P J Nathan, V L Villemagne, R S Mulligan, K A Ellis, H J Tochon-Danguy, J G Chan, G J O'keefe, J Bradley, G Savage, C C Row. The relationship between nicotinic receptors and cognitive functioning in healthy aging: An in vivo positron emission tomography (PET) study with 2-[(18)F]fluoro-A-85380. Synapse (New York, N.Y.). vol 63. issue 9. 2009-10-09. PMID:19484724. |
however, this approach may be appropriate for use in pathologies considered to undergo extensive nachr loss such as alzheimer's disease and parkinson's disease. |
2009-10-09 |
2023-08-12 |
human |
Simon N Haydar, Chiara Ghiron, Laura Bettinetti, Hendrick Bothmann, Thomas A Comery, John Dunlop, Salvatore La Rosa, Iolanda Micco, Martina Pollastrini, Joanna Quinn, Renza Roncarati, Carla Scali, Michela Valacchi, Maurizio Varrone, Riccardo Zanalett. SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist. Bioorganic & medicinal chemistry. vol 17. issue 14. 2009-10-08. PMID:19515567. |
alpha 7 nicotinic acetylcholine receptor (alpha(7) nachr) agonists are promising therapeutic candidates for the treatment of cognitive impairment associated with a variety of disorders including alzheimer's disease and schizophrenia. |
2009-10-08 |
2023-08-12 |
Not clear |
Milos D Ikonomovic, Lynn Wecker, Eric E Abrahamson, Joanne Wuu, Scott E Counts, Stephen D Ginsberg, Elliott J Mufson, Steven T Dekosk. Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease. Archives of neurology. vol 66. issue 5. 2009-09-09. PMID:19433665. |
to examine alpha7 nicotinic acetylcholine receptor (nachr) binding and beta-amyloid (abeta) peptide load in superior frontal cortex (sfc) across clinical and neuropathological stages of alzheimer disease (ad). |
2009-09-09 |
2023-08-12 |
Not clear |
Ruo-Xu Gu, Hui Gu, Zhi-Yuan Xie, Jing-Fang Wang, Hugo R Arias, Dong-Qing Wei, Kuo-Chen Cho. Possible drug candidates for Alzheimer's disease deduced from studying their binding interactions with alpha7 nicotinic acetylcholine receptor. Medicinal chemistry (Shariqah (United Arab Emirates)). vol 5. issue 3. 2009-07-28. PMID:19442215. |
dysfunction in alpha7 nicotinic acetylcholine receptor (nachr), a member of the cys-loop ligand-gated ion channel superfamily, is responsible for attentional and cognitive deficits in alzheimer's disease (ad). |
2009-07-28 |
2023-08-12 |
Not clear |
Marimuthu Parthiban, Mohan Babu Rajasekaran, Suryanarayanarao Ramakumar, Piramanayagam Shanmughave. Molecular modeling of human pentameric alpha(7) neuronal nicotinic acetylcholine receptor and its interaction with its agonist and competitive antagonist. Journal of biomolecular structure & dynamics. vol 26. issue 5. 2009-06-15. PMID:19236104. |
the nicotinic acetylcholine receptor (nachr) is the major class of neurotransmitter receptors that is involved in many neurodegenerative conditions such as schizophrenia, alzheimer's and parkinson's diseases. |
2009-06-15 |
2023-08-12 |
human |
Renza Roncarati, Carla Scali, Thomas A Comery, Steven M Grauer, Suzan Aschmi, Hendrick Bothmann, Brian Jow, Dianne Kowal, Marco Gianfriddo, Cody Kelley, Ugo Zanelli, Chiara Ghiron, Simon Haydar, John Dunlop, Georg C Terstappe. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. The Journal of pharmacology and experimental therapeutics. vol 329. issue 2. 2009-05-22. PMID:19223665. |
the alpha7 nicotinic acetylcholine receptor (nachr) is a promising target for treatment of cognitive dysfunction associated with alzheimer's disease and schizophrenia. |
2009-05-22 |
2023-08-12 |
rat |
Robert S Bitner, Arthur L Nikkel, Stella Markosyan, Stephani Otte, Pamela Puttfarcken, Murali Gopalakrishna. Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo. Brain research. vol 1265. 2009-05-13. PMID:19230830. |
the alpha7 nicotinic acetylcholine receptor (nachr) plays an important role in cognitive processes and has generated recent interest as a potential drug target for treating neurodegenerative disorders such as alzheimer's disease (ad). |
2009-05-13 |
2023-08-12 |
mouse |
Ru-yu Liu, Ran Gu, Xiao-lan Qi, Jia Chen, Jia-liu Liu, Zhi-zhong Gua. [Influence of beta-amyloid protein and cholesterol on the pathological changes of Alzheimer's disease and expression of nicotinic acetylcholine receptors in rats]. Zhonghua bing li xue za zhi = Chinese journal of pathology. vol 36. issue 3. 2009-04-21. PMID:17535686. |
to study the influence of beta-amyloid protein (abeta) and cholesterol on the pathological changes of alzheimer's disease (ad) and on the expression of nicotinic acetylcholine receptor (nachr) subunits in the brains of rats. |
2009-04-21 |
2023-08-12 |
rat |
Dominik Feuerbach, Kurt Lingenhoehl, Hans-Rudolf Olpe, Annick Vassout, Conrad Gentsch, Frederique Chaperon, Joachim Nozulak, Albert Enz, Graeme Bilbe, Kevin McAllister, Daniel Hoye. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology. vol 56. issue 1. 2009-04-02. PMID:18793655. |
several lines of evidence suggest that the nicotinic acetylcholine receptor alpha7 (nachr alpha7) is involved in central nervous system disorders like schizophrenia and alzheimer's disease as well as in inflammatory disorders like sepsis and pancreatitis. |
2009-04-02 |
2023-08-12 |
mouse |
John Dunlop, Tim Lock, Brian Jow, Fabrizio Sitzia, Steven Grauer, Flora Jow, Angela Kramer, Mark R Bowlby, Andrew Randall, Dianne Kowal, Adam Gilbert, Thomas A Comery, James Larocque, Veronica Soloveva, Jon Brown, Renza Roncarat. Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide). The Journal of pharmacology and experimental therapeutics. vol 328. issue 3. 2009-03-24. PMID:19050173. |
the alpha7 nicotinic acetylcholine receptor (nachr) has been implicated in alzheimer's disease and schizophrenia, leading to efforts targeted toward discovering agonists and positive allosteric modulators (pams) of this receptor. |
2009-03-24 |
2023-08-12 |
rat |
Edson X Albuquerque, Edna F R Pereira, Manickavasagom Alkondon, Scott W Roger. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiological reviews. vol 89. issue 1. 2009-02-26. PMID:19126755. |
with the advancement of functional and genetic studies in the late 1980s, the existence of nachrs in the mammalian brain was confirmed and the realization that the numerous nachr subtypes contribute to the psychoactive properties of nicotine and other drugs of abuse and to the neuropathology of various diseases, including alzheimer's, parkinson's, and schizophrenia, has since emerged. |
2009-02-26 |
2023-08-12 |
Not clear |
Zhi Tang, Yu An, Xiao-Lan Qi, Yan Xiao, Ke-Ren Shan, Zhi-Zhong Gua. Inhibiting gene expression of alpha3 nicotinic receptor in SH-SY5Y cells with the effects on APP metabolism and antioxidation in Alzheimer's disease. Neurochemistry international. vol 53. issue 5. 2009-02-02. PMID:18647633. |
in order to examine the effects of alpha3 nicotinic acetylcholine receptor (nachr) in connection with the pathogenesis of alzheimer's disease (ad), neuroblastoma (sh-sy5y) cells were transfected with small interference rnas (sirnas) that target specifically towards alpha3 nachr. |
2009-02-02 |
2023-08-12 |
Not clear |
Andreas Søderman, Morten S Thomsen, Henrik H Hansen, Elsebet Ø Nielsen, Morten S Jensen, Mark J West, Jens D Mikkelse. The nicotinic alpha7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice overexpressing human amyloid-beta1-42. Brain research. vol 1227. 2008-12-16. PMID:18619425. |
in accordance with observations in human alzheimer tissues, we show here through the use of co-immunoprecipitation that human abeta-immunoreactive peptides bind to mice alpha7 nachr in vivo. |
2008-12-16 |
2023-08-12 |
mouse |
Yan Xiao, Ke-ren Shan, Zhi-zhong Gua. [Effect of beta-amyloid peptides on alpha-7 nicotinic receptor status in astrocytes and neurons, and its relationship to pathogenesis of Alzheimer's disease]. Zhonghua bing li xue za zhi = Chinese journal of pathology. vol 35. issue 8. 2008-12-03. PMID:17069698. |
to study the alterations of alpha-7 nicotinic receptor (nachr) status in human brain tissues with alzheimer's disease (ad) and mouse brain tissues with swedish app670/671 gene mutation, and to study the effect of beta-amyloid peptides (a-beta) on alpha-7 nachr status in cultured astrocytes and neurons. |
2008-12-03 |
2023-08-12 |
mouse |
William H Bisson, Gerrit Westera, P Augustus Schubiger, Leonardo Scapozz. Homology modeling and dynamics of the extracellular domain of rat and human neuronal nicotinic acetylcholine receptor subtypes alpha4beta2 and alpha7. Journal of molecular modeling. vol 14. issue 10. 2008-11-03. PMID:18607650. |
in recent years, it has become clear that the neuronal nicotinic acetylcholine receptor (nachr) is a valid target in the treatment of a variety of diseases, including alzheimer's disease, anxiety, and nicotine addiction. |
2008-11-03 |
2023-08-12 |
human |